Monthly, PRN doses of ranibizumab similarly effective in RVO

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a stable disease state, according to results of the SHORE study presented here.The study compared efficacy of monthly and as-needed (PRN) dosing of intravitreal Lucentis (ranibizumab 0.5 mg, Genentech) in patients with retinal vein occlusion. “PRN treatment with ranibizumab in vein occlusion after reaching a stable disease state provides visual acuity gains comparable to monthly dosing over a 15-month period in retinal vein occlusion,” Dennis Marcus, MD, said at the (Read more...)

Full Story →